Phase 1/1B trial of the heat shock protein 90 inhibitor NVP-AUY922 as monotherapy or in combination with bortezomib in patients with relapsed or refractory multiple myeloma

Citation metadata

From: Cancer(Vol. 121, Issue 13)
Publisher: J.B. Lippincott Company
Document Type: Report

Document controls

Main content

Source Citation

Source Citation   

Gale Document Number: GALE|A421203205